Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-12-18

AUTHORS

P. D. Delmas, C. L. Benhamou, Z. Man, W. Tlustochowicz, E. Matzkin, R. Eusebio, J. Zanchetta, W. P. Olszynski, R. R. Recker, M. R. McClung

ABSTRACT

Postmenopausal women with osteoporosis received 75 mg risedronate on two consecutive days each month or 5 mg daily for 12 months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule.IntroductionPatients perceive less frequent dosing as being more convenient. This 2-year trial evaluates the efficacy and safety of a new monthly oral regimen of risedronate; 1 year results are presented here.MethodsPostmenopausal women with osteoporosis (n = 1229) were randomly assigned to double-blind treatment with 75 mg risedronate on two consecutive days each month (2CDM), or 5 mg daily. The primary endpoint was the percent change from baseline in lumbar spine (LS) bone mineral density (BMD) at month 12. Secondary efficacy was evaluated by mean percent changes from baseline in BMD in LS, total hip, trochanter, and femoral neck, and bone turnover markers (BTMs).ResultsRisedronate 75 mg 2CDM was non-inferior to 5 mg daily (treatment difference 0.21; 95% CI -0.19 to 0.62). Mean percent change in LS-BMD was 3.4% ± 0.16 and 3.6% ± 0.15 respectively. Mean percent changes in BMD and BTMs were significant and similar for both treatment groups. New vertebral fractures occurred in 1% of subjects with either treatment. Both treatments were generally well tolerated and safe.ConclusionsRisedronate 75 mg 2CDM was non-inferior in efficacy and did not show a difference in safety vs. 5 mg daily after 12 months, leading to a similar benefit. More... »

PAGES

1039-1045

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-007-0531-9

DOI

http://dx.doi.org/10.1007/s00198-007-0531-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046857184

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18087660


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Absorptiometry, Photon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etidronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Femur Neck", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lumbar Vertebrae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pelvic Bones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risedronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hopital Edouard Herriot, Pavillon F, 69437, Lyon, Cedex 03, France", 
          "id": "http://www.grid.ac/institutes/grid.412180.e", 
          "name": [
            "University of Lyon and INSERM Research Unit 831, Lyon, France", 
            "Hopital Edouard Herriot, Pavillon F, 69437, Lyon, Cedex 03, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delmas", 
        "givenName": "P. D.", 
        "id": "sg:person.012114001532.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012114001532.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM U658, Orl\u00e9ans, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "INSERM U658, Orl\u00e9ans, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benhamou", 
        "givenName": "C. L.", 
        "id": "sg:person.016622604354.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016622604354.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro Tiempo, Buenos Aires, Argentina", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centro Tiempo, Buenos Aires, Argentina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Man", 
        "givenName": "Z.", 
        "id": "sg:person.01320332045.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320332045.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Rheumatology, Military Institut of Medicine, Warszawa, Poland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine and Rheumatology, Military Institut of Medicine, Warszawa, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tlustochowicz", 
        "givenName": "W.", 
        "id": "sg:person.01104045466.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104045466.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "sanofi-aventis, Bridgewater, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417555.7", 
          "name": [
            "sanofi-aventis, Bridgewater, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matzkin", 
        "givenName": "E.", 
        "id": "sg:person.0652047633.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652047633.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Procter & Gamble Pharmaceuticals, Mason, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.418758.7", 
          "name": [
            "Procter & Gamble Pharmaceuticals, Mason, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eusebio", 
        "givenName": "R.", 
        "id": "sg:person.0720163033.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720163033.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituto de Investigaciones Metabolicas, Universidad del Salvador, Buenos Aires, Argentina", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Instituto de Investigaciones Metabolicas, Universidad del Salvador, Buenos Aires, Argentina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zanchetta", 
        "givenName": "J.", 
        "id": "sg:person.015266575153.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015266575153.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada", 
          "id": "http://www.grid.ac/institutes/grid.25152.31", 
          "name": [
            "Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Olszynski", 
        "givenName": "W. P.", 
        "id": "sg:person.012630456067.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012630456067.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osteoporosis Research Center, Creighton University, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/grid.254748.8", 
          "name": [
            "Osteoporosis Research Center, Creighton University, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Recker", 
        "givenName": "R. R.", 
        "id": "sg:person.016325222544.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oregon Osteoporosis Center, Portland, OR, USA", 
          "id": "http://www.grid.ac/institutes/grid.240531.1", 
          "name": [
            "Oregon Osteoporosis Center, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McClung", 
        "givenName": "M. R.", 
        "id": "sg:person.01202365465.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202365465.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001980050010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005303812", 
          "https://doi.org/10.1007/s001980050010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-002-2011-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041342659", 
          "https://doi.org/10.1007/s00223-002-2011-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1602-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036604057", 
          "https://doi.org/10.1007/s00198-004-1602-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-12-18", 
    "datePublishedReg": "2007-12-18", 
    "description": "Postmenopausal women with osteoporosis received 75\u00a0mg risedronate on two consecutive days each month or 5\u00a0mg daily for 12\u00a0months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75\u00a0mg twice monthly was effective and safe suggesting a new, convenient dosing schedule.IntroductionPatients perceive less frequent dosing as being more convenient. This 2-year trial evaluates the efficacy and safety of a new monthly oral regimen of risedronate; 1\u00a0year results are presented here.MethodsPostmenopausal women with osteoporosis (n\u2009=\u20091229) were randomly assigned to double-blind treatment with 75\u00a0mg risedronate on two consecutive days each month (2CDM), or 5\u00a0mg daily. The primary endpoint was the percent change from baseline in lumbar spine (LS) bone mineral density (BMD) at month 12. Secondary efficacy was evaluated by mean percent changes from baseline in BMD in LS, total hip, trochanter, and femoral neck, and bone turnover markers (BTMs).ResultsRisedronate 75\u00a0mg 2CDM was non-inferior to 5\u00a0mg daily (treatment difference 0.21; 95% CI -0.19 to 0.62). Mean percent change in LS-BMD was 3.4%\u2009\u00b1\u20090.16 and 3.6%\u2009\u00b1\u20090.15 respectively. Mean percent changes in BMD and BTMs were significant and similar for both treatment groups. New vertebral fractures occurred in 1% of subjects with either treatment. Both treatments were generally well tolerated and safe.ConclusionsRisedronate 75\u00a0mg 2CDM was non-inferior in efficacy and did not show a difference in safety vs. 5\u00a0mg daily after 12\u00a0months, leading to a similar benefit.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-007-0531-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "bone turnover markers", 
      "bone mineral density", 
      "mean percent change", 
      "percent change", 
      "turnover markers", 
      "consecutive days", 
      "mineral density", 
      "lumbar spine bone mineral density", 
      "spine bone mineral density", 
      "new vertebral fractures", 
      "double-blind treatment", 
      "oral regimen", 
      "MethodsPostmenopausal women", 
      "primary endpoint", 
      "monthly dosing", 
      "postmenopausal women", 
      "secondary efficacy", 
      "month 12", 
      "vertebral fractures", 
      "total hip", 
      "femoral neck", 
      "LS-BMD", 
      "frequent dosing", 
      "safety results", 
      "treatment groups", 
      "months", 
      "efficacy", 
      "osteoporosis", 
      "treatment", 
      "risedronate", 
      "dosing", 
      "similar benefits", 
      "baseline", 
      "women", 
      "year results", 
      "days", 
      "markers", 
      "safety", 
      "IntroductionPatients", 
      "regimen", 
      "hip", 
      "trochanter", 
      "neck", 
      "trials", 
      "endpoint", 
      "changes", 
      "subjects", 
      "fractures", 
      "group", 
      "differences", 
      "schedule", 
      "benefits", 
      "results", 
      "LS", 
      "density"
    ], 
    "name": "Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results", 
    "pagination": "1039-1045", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046857184"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-007-0531-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18087660"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-007-0531-9", 
      "https://app.dimensions.ai/details/publication/pub.1046857184"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_453.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-007-0531-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0531-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0531-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0531-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0531-9'


 

This table displays all metadata directly associated to this object as RDF triples.

284 TRIPLES      21 PREDICATES      100 URIs      89 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-007-0531-9 schema:about N015a7993e9484c8c8c72055dc1ae4d33
2 N040ea69a79394039bf79be8ad4b21db1
3 N0db83d2abd354634b06f692bb5535845
4 N306f0c152e464fb68e4ccf5693f2099d
5 N32aee01914884ffebd7bf2f216f31204
6 N36aee0660e5845c7a0db5cc77352621a
7 N44fd14d2efc24d059138bfcdf50d63fe
8 N5770d869b5ae4d7cae5c60574c975d47
9 N704e2c9111d94d428b655ecbe3533ff5
10 N74ffc76690a547b48807b404ad05f471
11 N7ba9203ecf6b46f3a6b7814e0ba2e2c7
12 N92523311cc6f45bd949766b60825aebc
13 N9ea6ff9e99114ce59d6d35f1b15d7577
14 Nd10e56bb4d7944cdb17d1634cf85448f
15 Nd4ef2721024c491a8132cb9aca7042d3
16 Nd8fc193492e547d19fd50a66c09860da
17 Nf7376c6c9fc94ad799f541675ba23669
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N0bc96dfffc154b6190141c7065a59aa6
21 schema:citation sg:pub.10.1007/s00198-004-1602-9
22 sg:pub.10.1007/s001980050010
23 sg:pub.10.1007/s00223-002-2011-8
24 schema:datePublished 2007-12-18
25 schema:datePublishedReg 2007-12-18
26 schema:description Postmenopausal women with osteoporosis received 75 mg risedronate on two consecutive days each month or 5 mg daily for 12 months. Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule.IntroductionPatients perceive less frequent dosing as being more convenient. This 2-year trial evaluates the efficacy and safety of a new monthly oral regimen of risedronate; 1 year results are presented here.MethodsPostmenopausal women with osteoporosis (n = 1229) were randomly assigned to double-blind treatment with 75 mg risedronate on two consecutive days each month (2CDM), or 5 mg daily. The primary endpoint was the percent change from baseline in lumbar spine (LS) bone mineral density (BMD) at month 12. Secondary efficacy was evaluated by mean percent changes from baseline in BMD in LS, total hip, trochanter, and femoral neck, and bone turnover markers (BTMs).ResultsRisedronate 75 mg 2CDM was non-inferior to 5 mg daily (treatment difference 0.21; 95% CI -0.19 to 0.62). Mean percent change in LS-BMD was 3.4% ± 0.16 and 3.6% ± 0.15 respectively. Mean percent changes in BMD and BTMs were significant and similar for both treatment groups. New vertebral fractures occurred in 1% of subjects with either treatment. Both treatments were generally well tolerated and safe.ConclusionsRisedronate 75 mg 2CDM was non-inferior in efficacy and did not show a difference in safety vs. 5 mg daily after 12 months, leading to a similar benefit.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N35d792d7fcb248609b86cc1bc79de7b6
30 Nb0783d1a614041d6bf9b80ebd6c22227
31 sg:journal.1100834
32 schema:keywords IntroductionPatients
33 LS
34 LS-BMD
35 MethodsPostmenopausal women
36 baseline
37 benefits
38 bone mineral density
39 bone turnover markers
40 changes
41 consecutive days
42 days
43 density
44 differences
45 dosing
46 double-blind treatment
47 efficacy
48 endpoint
49 femoral neck
50 fractures
51 frequent dosing
52 group
53 hip
54 lumbar spine bone mineral density
55 markers
56 mean percent change
57 mineral density
58 month 12
59 monthly dosing
60 months
61 neck
62 new vertebral fractures
63 oral regimen
64 osteoporosis
65 percent change
66 postmenopausal women
67 primary endpoint
68 regimen
69 results
70 risedronate
71 safety
72 safety results
73 schedule
74 secondary efficacy
75 similar benefits
76 spine bone mineral density
77 subjects
78 total hip
79 treatment
80 treatment groups
81 trials
82 trochanter
83 turnover markers
84 vertebral fractures
85 women
86 year results
87 schema:name Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
88 schema:pagination 1039-1045
89 schema:productId N401bb4c893c6404aa4fdc4657d785980
90 Nb7b214acc5f4426fa9438ac0c03047e8
91 Ne56ec526e9624151ba7b980308bcc453
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046857184
93 https://doi.org/10.1007/s00198-007-0531-9
94 schema:sdDatePublished 2022-08-04T16:56
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nf7fcd9bb719044e78f8244532f8aae72
97 schema:url https://doi.org/10.1007/s00198-007-0531-9
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N015a7993e9484c8c8c72055dc1ae4d33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Etidronic Acid
103 rdf:type schema:DefinedTerm
104 N040ea69a79394039bf79be8ad4b21db1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Double-Blind Method
106 rdf:type schema:DefinedTerm
107 N0bc96dfffc154b6190141c7065a59aa6 rdf:first sg:person.012114001532.25
108 rdf:rest Nca5bf5818b6347a1a8a0bef73dc2aa2e
109 N0db83d2abd354634b06f692bb5535845 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Middle Aged
111 rdf:type schema:DefinedTerm
112 N1b5b5580952f480a85fe8614a7c62fb4 rdf:first sg:person.016325222544.69
113 rdf:rest N62816ad29bd8430b8de87a60d3b8e04f
114 N306f0c152e464fb68e4ccf5693f2099d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Administration, Oral
116 rdf:type schema:DefinedTerm
117 N32aee01914884ffebd7bf2f216f31204 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Osteoporosis, Postmenopausal
119 rdf:type schema:DefinedTerm
120 N35d792d7fcb248609b86cc1bc79de7b6 schema:issueNumber 7
121 rdf:type schema:PublicationIssue
122 N36aee0660e5845c7a0db5cc77352621a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Lumbar Vertebrae
124 rdf:type schema:DefinedTerm
125 N401bb4c893c6404aa4fdc4657d785980 schema:name dimensions_id
126 schema:value pub.1046857184
127 rdf:type schema:PropertyValue
128 N43667988d335424481bcb31e577942af rdf:first sg:person.015266575153.41
129 rdf:rest Nbdbcf4e3fae84cc0b075951be3c2a477
130 N44fd14d2efc24d059138bfcdf50d63fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Absorptiometry, Photon
132 rdf:type schema:DefinedTerm
133 N5770d869b5ae4d7cae5c60574c975d47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Female
135 rdf:type schema:DefinedTerm
136 N62816ad29bd8430b8de87a60d3b8e04f rdf:first sg:person.01202365465.00
137 rdf:rest rdf:nil
138 N704e2c9111d94d428b655ecbe3533ff5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 N74ffc76690a547b48807b404ad05f471 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Pelvic Bones
143 rdf:type schema:DefinedTerm
144 N7ba9203ecf6b46f3a6b7814e0ba2e2c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Femur Neck
146 rdf:type schema:DefinedTerm
147 N92523311cc6f45bd949766b60825aebc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Risedronic Acid
149 rdf:type schema:DefinedTerm
150 N9764626ee030456cb310007d30a275f1 rdf:first sg:person.0652047633.68
151 rdf:rest Nbb5bdc206f0e4b318291bb91127ab488
152 N9ea6ff9e99114ce59d6d35f1b15d7577 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Aged
154 rdf:type schema:DefinedTerm
155 Na289a373172b484f8d181d73206cb248 rdf:first sg:person.01104045466.34
156 rdf:rest N9764626ee030456cb310007d30a275f1
157 Nb0783d1a614041d6bf9b80ebd6c22227 schema:volumeNumber 19
158 rdf:type schema:PublicationVolume
159 Nb7b214acc5f4426fa9438ac0c03047e8 schema:name pubmed_id
160 schema:value 18087660
161 rdf:type schema:PropertyValue
162 Nbb5bdc206f0e4b318291bb91127ab488 rdf:first sg:person.0720163033.36
163 rdf:rest N43667988d335424481bcb31e577942af
164 Nbdbcf4e3fae84cc0b075951be3c2a477 rdf:first sg:person.012630456067.49
165 rdf:rest N1b5b5580952f480a85fe8614a7c62fb4
166 Nca5bf5818b6347a1a8a0bef73dc2aa2e rdf:first sg:person.016622604354.88
167 rdf:rest Ne6376a364dc84be8b791bfb03d3be5aa
168 Nd10e56bb4d7944cdb17d1634cf85448f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Bone Density Conservation Agents
170 rdf:type schema:DefinedTerm
171 Nd4ef2721024c491a8132cb9aca7042d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Drug Administration Schedule
173 rdf:type schema:DefinedTerm
174 Nd8fc193492e547d19fd50a66c09860da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Treatment Outcome
176 rdf:type schema:DefinedTerm
177 Ne56ec526e9624151ba7b980308bcc453 schema:name doi
178 schema:value 10.1007/s00198-007-0531-9
179 rdf:type schema:PropertyValue
180 Ne6376a364dc84be8b791bfb03d3be5aa rdf:first sg:person.01320332045.74
181 rdf:rest Na289a373172b484f8d181d73206cb248
182 Nf7376c6c9fc94ad799f541675ba23669 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Bone Density
184 rdf:type schema:DefinedTerm
185 Nf7fcd9bb719044e78f8244532f8aae72 schema:name Springer Nature - SN SciGraph project
186 rdf:type schema:Organization
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
191 schema:name Clinical Sciences
192 rdf:type schema:DefinedTerm
193 sg:journal.1100834 schema:issn 0937-941X
194 1433-2965
195 schema:name Osteoporosis International
196 schema:publisher Springer Nature
197 rdf:type schema:Periodical
198 sg:person.01104045466.34 schema:affiliation grid-institutes:None
199 schema:familyName Tlustochowicz
200 schema:givenName W.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104045466.34
202 rdf:type schema:Person
203 sg:person.01202365465.00 schema:affiliation grid-institutes:grid.240531.1
204 schema:familyName McClung
205 schema:givenName M. R.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202365465.00
207 rdf:type schema:Person
208 sg:person.012114001532.25 schema:affiliation grid-institutes:grid.412180.e
209 schema:familyName Delmas
210 schema:givenName P. D.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012114001532.25
212 rdf:type schema:Person
213 sg:person.012630456067.49 schema:affiliation grid-institutes:grid.25152.31
214 schema:familyName Olszynski
215 schema:givenName W. P.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012630456067.49
217 rdf:type schema:Person
218 sg:person.01320332045.74 schema:affiliation grid-institutes:None
219 schema:familyName Man
220 schema:givenName Z.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320332045.74
222 rdf:type schema:Person
223 sg:person.015266575153.41 schema:affiliation grid-institutes:None
224 schema:familyName Zanchetta
225 schema:givenName J.
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015266575153.41
227 rdf:type schema:Person
228 sg:person.016325222544.69 schema:affiliation grid-institutes:grid.254748.8
229 schema:familyName Recker
230 schema:givenName R. R.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69
232 rdf:type schema:Person
233 sg:person.016622604354.88 schema:affiliation grid-institutes:None
234 schema:familyName Benhamou
235 schema:givenName C. L.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016622604354.88
237 rdf:type schema:Person
238 sg:person.0652047633.68 schema:affiliation grid-institutes:grid.417555.7
239 schema:familyName Matzkin
240 schema:givenName E.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652047633.68
242 rdf:type schema:Person
243 sg:person.0720163033.36 schema:affiliation grid-institutes:grid.418758.7
244 schema:familyName Eusebio
245 schema:givenName R.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720163033.36
247 rdf:type schema:Person
248 sg:pub.10.1007/s00198-004-1602-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036604057
249 https://doi.org/10.1007/s00198-004-1602-9
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s001980050010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005303812
252 https://doi.org/10.1007/s001980050010
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s00223-002-2011-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041342659
255 https://doi.org/10.1007/s00223-002-2011-8
256 rdf:type schema:CreativeWork
257 grid-institutes:None schema:alternateName Centro Tiempo, Buenos Aires, Argentina
258 Department of Internal Medicine and Rheumatology, Military Institut of Medicine, Warszawa, Poland
259 INSERM U658, Orléans, France
260 Instituto de Investigaciones Metabolicas, Universidad del Salvador, Buenos Aires, Argentina
261 schema:name Centro Tiempo, Buenos Aires, Argentina
262 Department of Internal Medicine and Rheumatology, Military Institut of Medicine, Warszawa, Poland
263 INSERM U658, Orléans, France
264 Instituto de Investigaciones Metabolicas, Universidad del Salvador, Buenos Aires, Argentina
265 rdf:type schema:Organization
266 grid-institutes:grid.240531.1 schema:alternateName Oregon Osteoporosis Center, Portland, OR, USA
267 schema:name Oregon Osteoporosis Center, Portland, OR, USA
268 rdf:type schema:Organization
269 grid-institutes:grid.25152.31 schema:alternateName Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
270 schema:name Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
271 rdf:type schema:Organization
272 grid-institutes:grid.254748.8 schema:alternateName Osteoporosis Research Center, Creighton University, Omaha, NE, USA
273 schema:name Osteoporosis Research Center, Creighton University, Omaha, NE, USA
274 rdf:type schema:Organization
275 grid-institutes:grid.412180.e schema:alternateName Hopital Edouard Herriot, Pavillon F, 69437, Lyon, Cedex 03, France
276 schema:name Hopital Edouard Herriot, Pavillon F, 69437, Lyon, Cedex 03, France
277 University of Lyon and INSERM Research Unit 831, Lyon, France
278 rdf:type schema:Organization
279 grid-institutes:grid.417555.7 schema:alternateName sanofi-aventis, Bridgewater, NJ, USA
280 schema:name sanofi-aventis, Bridgewater, NJ, USA
281 rdf:type schema:Organization
282 grid-institutes:grid.418758.7 schema:alternateName Procter & Gamble Pharmaceuticals, Mason, OH, USA
283 schema:name Procter & Gamble Pharmaceuticals, Mason, OH, USA
284 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...